Study S002553

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of VCT220 Tablets in Overweight/Obese Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

Included trial: extracted data ClinicalTrials.gov record

Registration

Registration: NCT06569355
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: QUADRUPLE
Status: COMPLETED
Enrollment: 250
Start: 2023-12-27
Primary completion: 2024-07-13
Lead sponsor: Vincentage Pharma Co., Ltd
Conditions: Obesity; Overweight
Interventions: DRUG:VCT220; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Percentage change in body weight [From baseline (week 1) to week 16]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0001121	Oral nonpeptide GLP-1 receptor agonist VCT220 for obesity treatment: a randomized, double-blind, phase II trial. Ji L, Signal transduction and targeted therapy	2026	Randomized trial	PMID 42595749 DOI	cites ClinicalTrials.gov:NCT06569355; registry reference DERIVED:42595749